# US 10,117,902 B2 · Nutritional composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,117,902 B2
- Document ID: US10117902B2
- Status: Granted
- Kind: B2
- Application number: 15/205,786
- Filed: 2016-07-08
- Published: 2016-11-03
- Granted: 2018-11-06
- Earliest claimed: 2013-03-28
- Assignees: Houn Simon Hsia
- Applicants: Houn Simon Hsia
- Inventors: Houn Simon Hsia
- Web page: https://patentgrep.com/patent/US10117902B2

## CPC

- A61K 36/064: Saccharomycetales, e.g. baker's yeast
- A23L 33/105: Plant extracts, their artificial duplicates or their derivatives
- A23L 33/115: Fatty acids or derivatives thereof; Fats or oils
- A23L 33/14: Yeasts or derivatives thereof
- A23L 33/15: Vitamins
- A23L 33/155: Vitamins A or D
- A23L 33/16: Inorganic salts, minerals or trace elements
- A23L 33/175: Amino acids
- A61K 31/015: carbocyclic
- A61K 31/05: Phenols {(cannabinoids A61K31/658)}
- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 31/18: Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63)
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557)
- A61K 31/24: having an amino or nitro group
- A61K 31/30: Copper compounds
- A61K 31/32: Tin compounds
- A61K 31/34: having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K 31/4415: Pyridoxine, i.e. Vitamin B6 (pyridoxal phosphate A61K31/675)
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/593: 9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
- A61K 33/18: Iodine; Compounds thereof
- A61K 33/24: Heavy metals; Compounds thereof
- A61K 33/30: Zinc; Compounds thereof
- A61K 33/32: Manganese; Compounds thereof
- A61K 33/34: Copper; Compounds thereof
- A61K 35/60: Fish, e.g. seahorses; Fish eggs
- A61K 36/06: Fungi, e.g. yeasts
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

The present invention provides nutritional compositions that are employed as oral supplementation to the human diet. The compositions of the present invention provide for supplementation to the diet of the cancer patient, as well as preventative dietary supplementation aimed at supporting the human immune system for those not currently suffering from cancer. The present invention is comprised of specific combinations of selected forms of unique sets of certain vitamins, minerals, protein, carbohydrates and phytochemicals.

## Claims

### Claim 1

A method of treatment of cancer cachexia and suppression of neoplastic growth in a cancer patient, the method comprising:
orally administering a nutritional composition to a cancer patient in need thereof, the nutritional composition comprising:
selenium in the form of selenium yeast;
0.5 mg to 1.5 g fish oil, the fish oil having a combined EPA/DHA content of between 10% to 90% and an EPA/DHA ratio of between 1:5and 5:1;
500 iu to 10,000 iu beta carotene;
a milk protein;
a rice protein; and
inositol,
wherein the nutritional composition is orally administered in an amount effective to both reduce cachectic symptoms and suppress neoplastic growth in the cancer patient.

### Claim 2 (depends on 1)

The method of claim 1, wherein the selenium yeast is in an amount from 10 μg to 250 μg.

### Claim 3 (depends on 1)

The method of claim 1, wherein the selenium yeast is in an amount from 25 μg to 1500 μg.

### Claim 4 (depends on 1)

The method of claim 1, wherein the selenium yeast is one or more of the group consisting of: Saccharomyces cerevisiae, Saccharomyces exiguous, Saccharomyces pastorianus, Saccharomyces boulardii, Saccharomyces bayanus, Saccharomyces eubayanus, Saccharomyces florentinus, and Saccharomyces fragilis.

### Claim 5 (depends on 1)

The method of claim 1, wherein the fish oil has an EPA/DHA content of between 30% to 70%.

### Claim 6 (depends on 1)

The method of claim 1, wherein the fish oil has an EPA/DHA content of between 40% to 60%.

### Claim 7 (depends on 1)

The method of claim 1, wherein the fish oil has an EPA/DHA ratio of about 2:1.

### Claim 8 (depends on 1)

The method of claim 1, wherein the fish oil has an EPA/DHA ratio of about 3:2.

### Claim 9 (depends on 1)

The method of claim 1, wherein the beta carotene is in an amount between 1500 iu and 7500iu.

### Claim 10 (depends on 1)

The method of claim 1, wherein the beta carotene is in an amount between 1000 iu and 3000iu.

### Claim 11 (depends on 1)

The method of claim 1, wherein the nutritional composition additionally comprises 5 mg to 1500 mg resveratrol-containing extract, the resveratrol containing extract comprising between 50% and 98% resveratrol.

### Claim 12 (depends on 1)

The method of claim 1, wherein the nutritional composition additionally comprises one or more vitamins, the one or more vitamins selected from the group of: between 50 iu and 3000 iu vitamin D3, between 2.5 μg to 250 μg vitamin K, between 0.1 mg to 100 mg vitamin B6, and between 0.3 μg to 900 μg vitamin B12.

### Claim 13 (depends on 1)

The method of claim 1, wherein the nutritional composition additionally comprises between 25 82 g to 1000 μg folic acid.

### Claim 14 (depends on 1)

The method of claim 1, wherein the nutritional composition additionally comprises one or more minerals, the one or more minerals being selected from the group of: between 0.65 μg to 4000 μg zinc, between 50 μg to 500 μg chromium, and between 2.5 μg to 1000 μg molybdenum.

### Claim 15 (depends on 1)

The method of claim 1, wherein the nutritional composition additionally comprises one or more amino acids, the one or more amino acids being selected from the group of: between 2.1 g to 250 g glutamine, between 0.71 g to 25 g arginine, between 1.1 g to 29 g taurine, and between 0.81 g to 48 g lysine.

### Claim 16 (depends on 1)

The method of claim 1, wherein the nutritional composition additionally comprises between 30 mg to 1000 mg coenzyme Q-10.

### Claim 17 (depends on 1)

The method of claim 1, wherein the milk protein is selected from the group consisting of whey protein, casein, and non-fat milk.

### Claim 18

A method of treatment of cancer cachexia and suppression of neoplastic growth in a cancer patient, the method comprising:
administering a nutritional composition to a cancer patient in need thereof, the nutritional composition consisting of:
selenium in the form of selenium yeast;
fish oil, the fish oil having a combined EPA/DHA content of between 10% to 90% and an EPA/DHA ratio of between 1:5and 5:1;
beta carotene;
vitamin D3 ;
vitamin K;
vitamin B6;
vitamin B12;
folic acid;
zinc;
chromium;
molybdenum;
glutamine;
argenine;
taurine;
lysine;
coenzyme Q
niacin;
riboflavin;
thiamin;
biotin;
calcium;
iron;
phosphorous;
iodine;
copper;
manganese;
inositol;
sucrose;
whey protein;
rice protein;
calcium caseinate; and
soy lecithin,
wherein the nutritional composition is orally administered in an amount effective to provide both a reduction in cachectic symptoms and suppression of neoplastic growth in the cancer patient.

### Claim 19

A method of treatment of cancer cachexia and suppression of neoplastic growth in a cancer patient, the method comprising:
orally administering a nutritional composition to a cancer patient in need thereof, the nutritional composition consisting of:
selenium in the form of selenium yeast;
fish oil, the fish oil having a combined EPA/DHA content of between 10% to 90% and an EPA/DHA ratio of between 1:5and 5:1;
beta carotene;
vitamin D3;
vitamin K;
vitamin B6;
vitamin B12;
folic acid;
iron;
phosphorous;
iodine;
copper;
manganese;
inositol;
sucrose;
whey protein;
rice protein;
calcium caseinate; and
soy lecithin,
wherein the nutritional composition is orally administered in an amount effective to provide both a reduction in cachectic symptoms and suppression of neoplastic growth in the cancer patient.

### Claim 20

A method of treatment of cancer cachexia and suppression of neoplastic growth in a cancer patient, the method comprising:
orally administering a nutritional composition to a cancer patient in need thereof, the nutritional composition consisting of:
selenium in the form of selenium yeast;
fish oil, the fish oil having a combined EPA/DHA content of between 10% to 90% and an EPA/DHA ratio of between 1:5and 5:1;
beta carotene;
vitamin D3;
vitamin K;
vitamin B6;
vitamin B12;
folic acid;
zinc;
chromium;
molybdenum;
glutamine;
argenine;
taurine;
lysine;
coenzyme Q
copper;
manganese;
inositol;
sucrose;
whey protein;
rice protein;
calcium caseinate; and
soy lecithin,
wherein the nutritional composition is orally administered in an amount effective to provide both a reduction in cachectic symptoms and suppression of neoplastic growth in the cancer patient.